Indeed, there are several recent studies investigating the efficacy of patritumab deruxtecan (HER3-Dxd) in various solid tumours such as HER2-negative breast cancer and EGFR-mutated NSCLC [115,116,117,118,119,120,121,122,123,124,125,126]. Here, ERBB2 is linked to non-small cell lung carcinoma.